Synutra International, Inc.  

(Public, NASDAQ:SYUT)   Watch this stock  
Find more results for SYUT
5.61
-0.10 (-1.75%)
Aug 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.61 - 5.74
52 week 3.90 - 9.50
Open 5.70
Vol / Avg. 86,748.00/50,515.00
Mkt cap 321.46M
P/E 19.21
Div/yield     -
EPS 0.29
Shares 57.30M
Beta 2.14
Inst. own 38%
Aug 10, 2012
Q1 2013 Synutra International Inc Earnings Conference Call - 8:00AM EDT - Add to calendar
Jun 26, 2012
Synutra International Inc at Oppenheimer Holdings Inc Consumer Conference
Jun 15, 2012
Q4 2012 Synutra International Inc Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '12) 2012
Net profit margin 8.73% 4.97%
Operating margin 18.97% 12.49%
EBITD margin - 15.93%
Return on average assets 6.99% 4.02%
Return on average equity 32.72% 19.54%
Employees 4,250 -
Carbon Disclosure Rating - -

Address

Suite 500, 2275 Research Blvd.
ROCKVILLE, MD 20850
United States - Map
+1-301-8403888 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Synutra International, Inc. (Synutra) is an infant formula company in China. The Company principally produces, markets, and sells its products under the Shengyuan or Synutra name, together with other complementary brands. It sells its products through sales and distribution network, including independent distributors, covering 30 provinces and provincial-level municipalities in China. It operates in three segments: the powdered formula segment, which includes powdered infant and adult formula products sold under its Super, U-Smart, Mingshan and Helanruniu sub-brands; the baby food segment, which includes prepared foods for babies and children sold under its Huiliduo sub-brand, and the nutritional ingredients and supplements segment, which includes the production and sale of nutritional ingredients and supplements, such as chondroitin sulfate, microencapsulated docosahexanoic acid (DHA) and arachidonic acid (ARA).

Officers and directors

Liang Zhang Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation - Reuters
Weiguo Zhang President, Interim Chief Financial Officer
Age: 55
Bio & Compensation - Reuters
Feng Zha Vice President - Human Resources and Administration
Age: 49
Bio & Compensation - Reuters
Xisen Mu Vice President - Production
Age: 55
Bio & Compensation - Reuters
Joseph Chow Director
Age: 50
Bio & Compensation - Reuters
Donghao Yang Director
Age: 40
Bio & Compensation - Reuters
Yiu-Chun Chan Independent Director
Age: 60
Bio & Compensation - Reuters
Jinrong Chen Independent Director
Age: 52
Bio & Compensation - Reuters
Hui Li Independent Director
Age: 44
Bio & Compensation - Reuters